A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

被引：0

作者：

Carducci, M. ^{[1
]}

Armstrong, A. ^{[2
,3
]}

Pili, R. ^{[4
]}

Ng, S. ^{[5
]}

Huddart, R. ^{[6
]}

Agarwal, N. ^{[7
]}

Khvorostenko, D. ^{[8
]}

Lyulko, O. ^{[9
]}

Brize, A. ^{[10
]}

Vogelzang, N. J. ^{[11
]}

Delva, R. ^{[12
]}

Harza, M. ^{[13
]}

Thanos, A. ^{[14
]}

James, N. ^{[15
]}

Werbrouck, P. ^{[16
]}

Boegemann, M. ^{[17
]}

Hutson, T. ^{[18
]}

Milecki, P. ^{[19
]}

Nederman, T. ^{[20
]}

Sternberg, C. ^{[21
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Duke Canc Inst, Div Med Oncol, Durham, NC USA

[3] Duke Canc Inst, Div Urol, Durham, NC USA

[4] Indiana Univ Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA

[5] St John God Hosp, Ivy Suite Canc Ctr, Subiaco, WA, Australia

[6] Royal Marsden Hosp, Clin Oncol, Sutton, Surrey, England

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Leningrad Reg Oncol Dispensary, St Petersburg, Russia

[9] Municipal Inst Zaporizhzhia Reg Clin Hosp, Dept Urol, Zaporizhzhya, Ukraine

[10] Riga Eastern Clin Univ Hosp, Latvian Oncol Ctr, Riga, Latvia

[11] US Oncol & Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[12] Ctr Reg Lutte Canc Paul Papin, Serv Oncol Med, Angers, France

[13] Fundeni Clin Inst, Dept Urol, Bucharest, Romania

[14] Hosp Athens, Urol Clin, Agios Savas Anticanc Oncol, Athens, Greece

[15] Univ Warwick, Canc Res Unit, Warwick, England

[16] AZ Groeninge, Dept Urol, Kortrijk, Belgium

[17] Univ Klinikum Munster, Klin & Polikklin Urol, Munster, Germany

[18] Texas Oncol PA, Collins Bldg, Dallas, TX USA

[19] Wielkopolskie Ctr Onkol, Dept Radiotherapy, Poznan, Poland

[20] Act Biotech AB, Clin Dev, Lund, Sweden

[21] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31934-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4BA

引用

页码：S713 / S714

页数：2

共 50 条

[21] Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
Kelly, William Kevin
Halabi, Susan
Carducci, Michael
George, Daniel
Mahoney, John F.
Stadler, Walter M.
Morris, Michael
Kantoff, Philip
Monk, J. Paul
Kaplan, Ellen
Vogelzang, Nicholas J.
Small, Eric J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1534 - 1540
[22] A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC).
Attard, Gerhardt
Borre, Michael
Gurney, Howard
Loriot, Yohann
Andresen, Corina
Kalleda, Ranjith
Pham, Trinh
Taplin, Mary-Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] PROSPER: A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study of Enzalutamide in Menwith Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Gurneyon, Howard
Hussain, Maha
Fizazi, Karim
Saad, Fred
Rathenborg, Per
Shore, Neal D.
Demirhan, Eren
Modelska, Katharina
De Phung
Krivoshik, Andrew
Sternberg, Cora N.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 34 - 35
[24] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DENOSUMAB IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER
Smith, M. R.
Egerdie, B.
Hernandez Toriz, N.
Feldman, R.
Tammela, T. L. J.
Saad, F.
Urban, M.
Szwedowski, M.
Ke, C.
Kupic, A.
Leder, B.
Goessl, C.
EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 332 - 332
[25] Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study
Uemura, Hirotsugu
Arai, Gaku
Uemura, Hiroji
Suzuki, Hiroyoshi
Iijima, Kazuyoshi
Nishimura, Kazuo
Fujii, Koji
Hatayama, Tomoyoshi
Aoyama, Junya
Deprince, Kris
Lopez-Gitlitz, Angela
McCarthy, Sharon
Larsen, Julie S.
Li, Jinhui
Chi, Kim N.
INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (03) : 280 - 287
[26] TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
Kim, T. W.
Shen, L.
Xu, J. M.
Sriuranpong, V.
Pan, H.
Xu, R.
Han, S-W.
Liu, T.
Park, Y. S.
Shir, C.
Bai, Y.
Bi, F.
Ahn, J. B.
Qin, S.
Li, Q.
Wu, C.
Zhou, F.
Ma, D.
Srimuninnimit, V.
Li, J.
ANNALS OF ONCOLOGY, 2016, 27
[27] Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)
Tannock, Ian
Fizazi, Karim
Ivanov, Sergey
Thellenberg-Karlsson, Camilla
Flechon, Aude
Skoneczna, Iwona Anna
Orlandi, Francisco Jorquera
Gravis, Gwenaelle
Matveev, Vsevolod
Bavbek, Sevil E.
Gil, Thierry
Viana, Luciano S.
Aren, Osvaldo
Karyakin, Oleg
Elliott, Tony
Birtle, Alison J.
Magherini, Emmanuelle
Petrylak, Daniel Peter
Tombal, Bertrand
Rosenthal, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
Baskin-Bey, Edwina S.
Shore, Neal D.
Barber, Kenya
Ouatas, Taoufik
Heidenreich, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[29] A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN)
Rexer, H.
Hammerer, P.
UROLOGE, 2016, 55 (03): : 395 - 397
[30] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
Goodman, A. D.
Rossman, H.
Bar-Or, A.
Miller, A.
Miller, D. H.
Schmierer, K.
Lublin, F.
Khan, O.
Bormann, N. M.
Yang, M.
Panzara, M. A.
Sandrock, A. W.
NEUROLOGY, 2009, 72 (09) : 806 - 812

← 1 2 3 4 5 →